Surrozen (NASDAQ:SRZN) Stock Drops 2.7%

Analysts Weigh In on What's Next for the Biotech Firm

Mar. 14, 2026 at 5:54am

Got story updates? Submit your updates here. ›

Surrozen, Inc. (NASDAQ:SRZN), a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies targeting the Wnt signaling pathway, saw its share price drop 2.7% during trading on Friday. The stock traded as low as $23.43 and closed at $25.21, with approximately 164,020 shares changing hands.

Why it matters

Surrozen's stock performance and analyst coverage are closely watched by investors as the company continues to advance its pipeline of Wnt-targeting therapies for tissue repair, regeneration, and oncology applications. The Wnt signaling pathway is critical for cell proliferation, differentiation, and homeostasis, making it an important target for drug development.

The details

Wall Street analysts have provided a mixed outlook on Surrozen's stock. Cantor Fitzgerald initiated coverage with an "overweight" rating and a $40 price target, while Weiss Ratings maintained a "sell (d-)" rating. One analyst has a "Strong Buy" recommendation, two have a "Buy" rating, and one has a "Sell" rating on the stock, according to data from MarketBeat.com.

  • Surrozen's share price dropped 2.7% during trading on Friday, March 14, 2026.

The players

Surrozen, Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology.

Cantor Fitzgerald

An investment bank that initiated coverage on Surrozen with an "overweight" rating and a $40 price target.

Weiss Ratings

A research firm that maintained a "sell (d-)" rating on Surrozen's stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Surrozen's stock performance and analyst coverage highlight the ongoing interest and uncertainty surrounding the company's Wnt-targeting therapies, which have the potential to address a range of diseases but also face competition and regulatory hurdles. Investors will continue to closely monitor the company's progress as it advances its pipeline.